Clinical trials
Lung Cancer Screening clinical trials
Below are recruiting lung cancer screening clinical trials, each written for real people, not researchers. We’re tracking 698 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07140016RecruitingPhase 1
Study of gilteritinib for advanced ALK-positive lung cancer
This trial tests an oral drug called gilteritinib for people with advanced ALK-positive non-small cell lung cancer that has progressed after prior ALK inhibitor treatment. It aims to see if gilteritinib can help when other treatments have stopped working.
Fullerton, CaliforniaAges 18 years+ - NCT07590531RecruitingPhase 1/Phase 2
Two-Drug Lung Cancer Treatment Study
This trial tests a combination of two experimental drugs (AMT-116 and ivosidan) for patients with advanced lung cancer that cannot be removed by surgery. The study aims to see if this combination can help shrink tumors and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT06617936RecruitingPhase 2
Immunotherapy plus endostatin and chemo for stage III lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab), an anti-angiogenic drug (endostatin), and standard chemotherapy for people with stage III lung cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
Jinan, ShandongAges 18–75 - NCT06568939RecruitingPhase 2
Study of telisotuzumab vedotin for non-squamous lung cancer
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
Chandler, ArizonaAges 18 years+ - NCT07689643RecruitingEarly Phase 1
Radioactive drug plus immunotherapy for FAP-positive lung cancer
This trial tests a new treatment that uses a radioactive medicine called [177Lu]Lu-RTX-2358 combined with immunotherapy (a type of drug that helps your immune system fight cancer). It is for people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.
Wuhan, HubeiAges 18 years+ - NCT07416474RecruitingPhase 3
Comparing two drug combos for first-line lung cancer
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
Hefei, AnhuiAges 18–75 - NCT04302025RecruitingPhase 2
Testing targeted and immunotherapy before lung cancer surgery
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Duarte, CaliforniaAges 18 years+ - NCT05978284RecruitingPhase 1/Phase 2
Study of ZG006 for small cell lung cancer or neuroendocrine carcinoma
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
Zhengzhou, HenanAges 18–75 - NCT06230445RecruitingPhase 3
Digital health app for lung cancer management
This trial tests a digital health app to help manage the entire treatment process for lung cancer. It may assist patients who are already undergoing or have completed treatments like surgery or chemotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06417814RecruitingPhase 3
Study of Dato-DXd with or without osimertinib for EGFR-mutated lung cancer
This trial tests a new drug, Dato-DXd, given alone or with osimertinib, versus standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after osimertinib treatment.
Fayetteville, ArkansasAges 18–130 - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Goodyear, ArizonaAges 18 years+ - NCT07337096Recruiting
Electro-acupuncture for advanced lung cancer: the EALER study
This study tests whether adding electro-acupuncture (a gentle type of acupuncture with mild electrical pulses) to standard first-line immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer. It aims to see if this combination improves quality of life and overall treatment outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT01786590Recruiting
Ultrasound biopsy to stage lung cancer before SBRT
This trial looks at using a scope with an ultrasound tip (EBUS-TBNA) to take small tissue samples from lymph nodes to figure out the cancer stage before stereotactic body radiotherapy (SBRT). The goal is to help confirm how far the cancer has spread so SBRT can be planned appropriately.
Toronto, OntarioAges 18 years+ - NCT06773156Enrolling by invitationPhase 2
Adebrelimab plus apatinib after chemoradiation for limited-stage SCLC
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Nanchang, JiangxiAges 18–75 - NCT05882058RecruitingPhase 2
Dose test of a DLL3 cancer drug for neuroendocrine tumors
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
Mobile, AlabamaAges 18 years+ - NCT06413212Recruiting
Personalized drug test for advanced cancer with fluid buildup
This trial uses a special test on your cancer cells to find which chemotherapy might work best for you. The aim is to treat advanced cancer that has caused fluid buildup in the chest or abdomen.
Wuhan, HubeiAges 18 years+ - NCT07565532Recruiting
Small Cell Lung Cancer Treatment Study With Radiation
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06555588Recruiting
Supportive talk therapy for advanced cancer symptoms
This study tests a supportive talk therapy program (called Engage) delivered via video calls. It aims to help people with advanced cancer manage tough symptoms like pain, fatigue, and distress and improve daily functioning.
Durham, North CarolinaAges 18 years+ - NCT06864338Recruiting
Pilot study for a new colorectal cancer screening test
This study tests a new stool-based test for detecting colorectal cancer and advanced polyps. It aims to see how well it works compared to a colonoscopy. The results may lead to a simpler screening option.
Morrisville, North CarolinaAges 18 years+ - NCT05358548RecruitingPhase 2
Alternating treatment for advanced lung and head-neck cancers
This Phase 2 study tests an approach that alternates treatments for advanced lung cancer or recurrent/metastatic head and neck squamous cell cancer. It may help by improving how well the cancer responds while managing side effects differently than standard back-to-back therapy.
Elizabeth, New JerseyAges 18 years+ - NCT07001618RecruitingPhase 2
Fecal transplant with immunotherapy for advanced lung cancer
This trial tests whether taking an oral fecal transplant (MaaT033) along with the immunotherapy drug cemiplimab can help people whose lung cancer stopped responding after antibiotics. It's for people with advanced non-small cell lung cancer whose cancer got worse after standard immunotherapy.
DijonAges 18 years+ - NCT07513376RecruitingPhase 3
Adjuvant vaccine plus immunotherapy for high-risk early lung cancer
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
Sacramento, CaliforniaAges 18 years+ - NCT06077760RecruitingPhase 3
Personalized cancer vaccine plus Keytruda for lung cancer after surgery
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
Anchorage, AlaskaAges 18 years+
Hear when a new Lung Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer screening?
- Yes. Clin2 currently lists 698 recruiting lung cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.